1242268-17-2

Basic information

• Product Name: 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate
• Synonyms: 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate
• CAS NO: 1242268-17-2
• Molecular Formula: C₁₅H₂₅NO₄
• Molecular Weight: 283.37
• EINECS: -0
• Mol File: 1242268-17-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 361.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.18±0.40(Predicted)
• CAS DataBase Reference: 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate(1242268-17-2)
• EPA Substance Registry System: 6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate(1242268-17-2)

Safety Data

• Hazardous Substances Data: 1242268-17-2(Hazardous Substances Data)

Usage

General Description

6-O-tert-butyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate is a chemical compound with a complex molecular structure. It is a dicarboxylate ester composed of a spiro ring system and two carboxylate groups. The compound contains a tert-butyl group and an ethyl group attached to different positions on the spiro ring. This chemical may have potential applications in pharmaceutical research and drug development due to its unique structure and potential biological activity. However, further research and testing would be needed to determine its specific properties and potential uses.

Upstream product

• 1774-47-6 trimethylsulfoxonium iodide 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 

Downstream Products

• 871727-05-8 (±)-6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid 
• 1453272-51-9 tert-butyl 1-[[(1S)-1-phenylethyl]carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate 
• 1160247-14-2 tert-butyl 1-carbamoyl-6-azaspiro[2.5]octane-6-carboxylate 
• 1416173-78-8 tert-butyl 1-{3-[4-(methanesulfonyl)phenoxy]propyl}-6-azaspiro[2.5]octane-6-carboxylate 
• 1416173-81-3 tert-butyl 1-{2-[4-(methanesulfonyl)phenoxy]ethyl}-6-azaspiro[2.5]octane-6-carboxylate 

Relevant articles and documents

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

GLP-1 Receptor Agonists and Uses Thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS

Heteroaryl pyridone and aza-pyridone amide compounds of Formula (I) are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.